Shanghai Henlius Biotech Initiates Phase 2 Study of HLX43 for Lung Cancer

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.

Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in an international multicentre phase 2 clinical study of HLX43, an anti-PD-L1 antibody-drug conjugate, for advanced non-small cell lung cancer in mainland China. This study aims to evaluate the efficacy and safety of HLX43, with the primary endpoint being the objective response rate. The phase 1 clinical trial results showed promising safety profiles and anti-tumor activity, particularly in non-small cell lung cancer and thymic squamous cell carcinoma, indicating potential positive implications for the company’s market positioning and stakeholders.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a biotechnology company focused on developing innovative biologic drugs, particularly in the field of oncology. The company specializes in antibody-drug conjugates and has a strong market focus on advanced and metastatic solid tumors, including non-small cell lung cancer.

Average Trading Volume: 1,429,186

Technical Sentiment Signal: Buy

Current Market Cap: HK$24.78B

For an in-depth examination of 2696 stock, go to TipRanks’ Stock Analysis page.